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Background: Although multiple low-osmolar iodinated contrast media (LOCM) options exist, in-hospital hemodialysis (HD) and mortality rates 
following their use in invasive cardiac catheterization procedures remain unknown.
Methods: : We performed a retrospective analysis using the Premier Perspective™ database which contains patient-level data including primary 
and secondary diagnosis and procedure codes. Inpatient adults without prior HD who underwent invasive cardiac catheterization procedures 
with LOCM during 2007-2008 were studied. Individuals were categorized for exposure to iohexol (n=36,118), iopamidol (n=36,089), ioversol 
(n=135,619). Multivariate logistic regression analysis was used to compare subsequent in-hospital HD and mortality after LOCM exposure. 
Statistical models included adjustment for: age, gender, race, reason for admission, hospital type, traditional cardiac risk factors, congestive heart 
failure, use of nephrotoxic agents, acute and chronic kidney injury, severity of illness, and >10 other comorbidities.
Results: In-hospital HD rates were low after exposure to any LOCM agent (0.8% iohexol vs. 1.0% iopamidol vs. 1.0% ioversol). Risk of HD did not 
differ between iopamidol and iohexol, although ioversol demonstrated increased risk of HD as compared to iohexol (Odds Ratio [OR] 1.28, 95% 
CI 1.11-1.45). In-hospital mortality risk was similar after LOCM use with iopamidol (OR 0.94, 95% CI 0.83-1.07) and with ioversol (OR 1.0, 95% CI 
0.90-1.1), as compared to iohexol (reference).
Conclusions: In this large cohort of hospitalized patients undergoing invasive catheterization procedures with LOCM, low rates of subsequent HD 
were observed after LOCM exposure with increased rates for ioversol use. No significant differences in in-hospital mortality existed for use of any 
LOCM agent.
